+1 more
Substituted phenethylamineamphetamine, methamphetamine, methylphenidate +2 moreamphetamine, methamphetamine, methylphenidate, cocaine, dopaminergic stimulants show less
2-FA
2-fluoroamphetamine
2-FA (2-fluoroamphetamine) is a synthetic stimulant of the substituted amphetamine class. It is a close structural analog of amphetamine, distinguished by an unusually short duration of action. It releases dopamine and norepinephrine into the brain, producing focused alertness and motivation.
2-FA (2-fluoroamphetamine) is a synthetic stimulant of the substituted amphetamine class. It is a close structural analog of amphetamine, distinguished by its unusually short duration of action. 2-FA is a presumed dopamine and norepinephrine releasing agent, producing its effects by displacing stored monoamines into the synapse.
+1 more
Substituted phenethylamineamphetamine, methamphetamine, methylphenidate +2 moreamphetamine, methamphetamine, methylphenidate, cocaine, dopaminergic stimulants show less
2-FA first appeared on research chemical markets in the early 2000s with no pharmaceutical history or clinical development behind it.[1] It was first detected in human biological samples in Denmark in 2010, in driving-under-the-influence cases.[2] It remains available through grey-market vendors, typically covered by analog laws or blanket NPS legislation rather than explicit scheduling.
Subjective effects include wakefulness, sharpened focus, motivation, and physical stimulation. The experience is clean and functional — task-oriented alertness without emotional warmth or body load, closer in character to d-amphetamine than to MDMA-adjacent stimulants. At higher doses the balance tips toward anxiety and overstimulation rather than greater reward.
Dependence liability is moderate; the main physical dangers are cardiovascular — raised blood pressure, rapid heart rate, and arrhythmia risk. The short duration drives compulsive redosing, and rodent data confirm 2-FA produces an internal state comparable to methamphetamine.[3] It is among the least-studied stimulants in active use — the first dedicated pharmacological study appeared in 2025,[3] and no human clinical data exist.
History[edit]
History
Synthesis and emergence
The original synthesis of 2-FA is undocumented — no pharmaceutical patent, clinical investigation, or research program has ever been associated with it. It appeared on research chemical markets in the early 2000s,[1] part of a wave of novel stimulants sold as legal alternatives to controlled amphetamines.
Forensic detection and fatal case
2-FA was first confirmed in human biological samples in 2010, when three driving-under-the-influence cases in Denmark returned positive results.[2] A 2019 fatal polydrug case in Germany involved 2-FA alongside designer benzodiazepines; death was attributed to combined respiratory depression, not to 2-FA alone.[4] These cases also revealed that standard GC-MS cannot reliably distinguish 2-FA from its positional isomers.[2]
Regulatory and scientific milestones
The EMCDDA flagged 2-FA through its Early Warning System by 2012.[5] Germany's NpSG and the UK's Psychoactive Substances Act (both 2016)[6] brought it under blanket NPS controls. The first dedicated pharmacological study appeared in 2025, confirming methamphetamine-like properties and significant abuse potential.[3]
The name 2-FA follows the convention for fluorinated amphetamine positional isomers: the numeral marks the ring position of the fluorine atom (ortho), distinguishing it from 3-FA (meta) and 4-FA (para). In research chemical communities, 2-FA is known as a "functional stimulant" — valued for productivity over recreation, and often described as milder and shorter-acting than its N-methyl homolog 2-FMA.
Chemistry[edit]
Chemistry
Structure
2-FA belongs to the substituted amphetamine class — it is the amphetamine molecule with a single fluorine atom at the ortho (2-) position of the phenyl ring.[7] This placement distinguishes it from 3-FA (meta) and 4-FA (para), which carry the same halogen at different ring positions.[7] 2-FA is also the N-desmethyl metabolite of 2-FMA (2-fluoromethamphetamine) — meaning the body produces 2-FA when it breaks down 2-FMA.[1]
| Molecular formula | C₉H₁₂FN |
| Molecular weight | 153.20 g/mol |
Analytical identification
2-FA circulates as a racemic mixture of two mirror-image molecular forms.[8] Standard GC-MS cannot distinguish it from the positional isomers 3-FA and 4-FA — all three produce near-identical fragmentation patterns.[2] Definitive identification requires UPLC-MS/MS,[2] infrared ion spectroscopy,[9] or chirality HPLC[7] — meaning standard drug checking cannot reliably confirm which fluoroamphetamine isomer is present.
Pharmacology[edit]
Pharmacology
Mechanism of action
No published binding data exist for 2-FA at any monoamine transporter, so the mechanism is inferred from amphetamine pharmacology and 2-FA's demonstrated methamphetamine-like behaviour in animals.[3] 2-FA is presumed to enter presynaptic nerve terminals via the dopamine and norepinephrine transporters, disrupt vesicular storage,[10][11] and reverse the transporter to push stored monoamines into the synapse.[10] The result is elevated dopamine and norepinephrine without the neuron needing to fire.
In vivo evidence
The only published pharmacological study appeared in 2025.[3] In mice, 2-FA produced locomotor stimulation comparable to methamphetamine. In rats trained to identify methamphetamine, 2-FA fully substituted — indicating both compounds produce a similar internal state.[3]
Pharmacokinetics
No human pharmacokinetic data exist; oral onset is 15–30 minutes and total duration 2–4 hours — notably shorter than amphetamine (4–6 hours). Metabolic routes are unstudied, but by analogy with 2-FMA, N-demethylation and hydroxylation are likely.[1] Forensic blood data from Danish driving cases[2] and a fatal German polydrug case[4] exist but cannot serve as dosing guidance.
Neuroscience[edit]
Neuroscience
No neuroimaging or neurochemical study has been published for 2-FA. The framework below is drawn from established amphetamine neuroscience, applied on the basis of 2-FA's methamphetamine-like behavioural profile in animals.[3]
Where it acts
Amphetamine-type releasing agents flood the brain's reward hub — the nucleus accumbens — with dopamine, and activate norepinephrine circuits governing arousal and focus. At moderate doses, this sharpens thinking and sustains motivation. At higher doses, the same circuits overshoot: excessive dopamine and norepinephrine tip the experience from focus into anxiety, restlessness, and thought acceleration.
Why it matters
Dopamine primarily drives wanting — the compulsion to seek — not the pleasure of having. Amphetamine-class compounds amplify this wanting disproportionately, which is why users describe strong motivation and a drive to redose without euphoria scaling to match. Repeated exposure also produces sensitisation — a progressive strengthening of reward-circuit responses thought to underlie escalating use patterns.
- Why is the duration so short? At 2–4 hours, 2-FA lasts roughly half as long as amphetamine. Faster liver clearance, rapid redistribution from the brain, or within-session tolerance could explain it — but no pharmacokinetic data exist to test these hypotheses.
- Does 2-FA cause neurotoxicity? Some para-substituted amphetamines are established neurotoxins. Whether ortho-fluorination causes nerve terminal damage with repeated use is entirely unknown.[12]
Subjective Effects[edit]
Subjective Effects
2-FA produces a state dominated by cognitive and physical stimulation with minimal euphoria. The defining quality is functional clarity — focused, task-oriented alertness that reads as clean rather than warm or emotionally expansive. At higher doses, restlessness and anxiety displace the focus.
Among the fluoroamphetamine isomers, 2-FA sits closest to d-amphetamine in character — purely dopaminergic, without the serotonergic warmth that defines 4-FA. Compared to its N-methyl homolog 2-FMA, 2-FA is shorter-acting and milder, positioned as a brief functional stimulant rather than a recreational euphoriant.
Fluorinated amphetamine analogs began circulating on research chemical markets in the early 2000s,[1] though 2-FA's original synthesis date is undocumented. It was first confirmed in human biological samples in Danish forensic cases in 2010.[2] It remains available on grey-market platforms in several jurisdictions, typically covered by analog or blanket NPS legislation rather than explicit scheduling.
Subjective effects include cognitive enhancement, wakefulness, motivation enhancement, and physical stimulation. The experience is defined by its clean, functional character — a focused, task-oriented alertness without the emotional warmth or body load associated with more serotonergic stimulants. Anxiety, overstimulation, and restlessness at higher doses are characteristic unsought effects.
Dependence liability is rated moderate, and no lethal dose has been established in any species. The short duration encourages compulsive redosing, and rodent data demonstrate full substitution for methamphetamine — a finding consistent with significant abuse potential.[3] 2-FA is among the least formally characterized stimulants in active circulation — the first dedicated pharmacological study appeared only in 2025,[3] and no human pharmacokinetic or clinical data exist.
History[edit]
History
Synthesis and emergence
The date and context of 2-FA's first synthesis are undocumented. Fluorinated amphetamines as a structural class have been known since the mid-20th century, but no pharmaceutical development, patent, or clinical investigation has ever been associated with 2-FA. It appeared on research chemical markets in the early 2000s[1] as part of a broader wave of novel psychoactive substances marketed as legal alternatives to controlled stimulants.
Forensic detection and fatal case
2-FA was first confirmed in human biological samples in 2010, when three driving-under-the-influence cases in eastern Denmark returned positive results.[2] In 2019, a fatal polydrug case in Germany involved 2-FA alongside designer benzodiazepines; death was attributed to combined CNS depression rather than to 2-FA alone.[4] These cases highlighted the forensic challenge of distinguishing 2-FA from its positional isomers, which produce near-identical mass spectra under standard GC-MS.[2]
Regulatory and scientific milestones
The EMCDDA flagged 2-FA through its Early Warning System by 2012.[5] Germany's NpSG (2016) and the UK's Psychoactive Substances Act (2016)[6] brought it under blanket NPS controls. The first dedicated pharmacological study appeared only in 2025, when rodent behavioural data confirmed methamphetamine-like properties and significant abuse potential.[3] As of 2026, no human clinical or pharmacokinetic study has been published.
The name 2-FA follows the systematic convention for fluorinated amphetamine positional isomers: the numeral denotes the ring position of the fluorine atom (ortho), distinguishing it from 3-FA (meta) and 4-FA (para). In research chemical communities, 2-FA occupies a niche as a "functional stimulant" — valued for productivity rather than recreation, and often compared unfavourably to its N-methyl homolog 2-FMA, which is regarded as more potent and longer-lasting.
Chemistry[edit]
Chemistry
Structure
2-FA belongs to the substituted phenethylamine and substituted amphetamine classes. Its core scaffold is amphetamine (1-phenylpropan-2-amine) with a single fluorine atom at the ortho (2-) position of the phenyl ring. This placement distinguishes it from 3-FA (meta) and 4-FA (para), which carry the same halogen at different ring positions.[7] 2-FA is also the N-desmethyl metabolite of 2-fluoromethamphetamine (2-FMA).[1]
| Molecular formula | C₉H₁₂FN |
| Molecular weight | 153.20 g/mol |
Structure-activity relationships
The position of the fluorine atom on the phenyl ring has pronounced pharmacological consequences. Para-halogenation (as in 4-FA) increases SERT activity, producing entactogenic warmth absent from the ortho isomer.[8] Ortho-substitution introduces steric bulk near the amine and alpha-methyl groups, potentially altering how the molecule interacts with monoamine transporters — though no published computational or crystallographic study has characterised this for 2-FA.
Stereochemistry
2-FA has one chirality centre at the alpha-carbon, yielding (R)- and (S)-enantiomers. The compound circulates as a racemic mixture.[9] By analogy with amphetamine — where the (S)-enantiomer is three to five times more potent at dopamine release — the (S)-enantiomer of 2-FA likely carries greater pharmacological activity, but no published comparison exists.[7][9]
Analytical identification
Standard GC-MS cannot reliably distinguish 2-FA from its positional isomers 3-FA and 4-FA, as all three produce near-identical fragmentation patterns. Definitive identification requires UPLC-MS/MS with retention time comparison,[2] infrared ion spectroscopy,[10] or chiral HPLC.[7] This limitation has direct implications for forensic casework and reagent-based drug checking, where positional isomer identity may be incorrectly assigned.
Pharmacology[edit]
Pharmacology
Mechanism of action
No published binding affinity data exist for 2-FA at any monoamine transporter or receptor. The mechanism described below is inferred from the well-established pharmacology of the amphetamine class, supported by 2-FA's demonstrated methamphetamine-like behavioural profile in rodents.[3]
2-FA is presumed to act as a substrate-type monoamine releasing agent at the DAT (DAT) and NET (NET). The amphetamine-class mechanism works through three converging processes: the compound enters presynaptic terminals via the transporter, disrupts vesicular storage by interfering with VMAT2,[11][12] and reverses the direction of the plasma membrane transporter to push accumulated monoamines into the synapse.[11] The net result is elevated dopamine and norepinephrine in the synaptic cleft without requiring the neuron to fire.
Serotonin transporter (SERT) activity has not been measured. The positional isomer 4-FA shows substantially greater serotonin release, producing entactogenic effects and increased serotonergic risk.[8] 2-FA's purely stimulant subjective profile — no reported emotional warmth or empathogenic quality — suggests that ortho-fluorination does not confer the same serotonin enhancement, though this inference rests on user reports rather than transporter assay data. inferred
In vivo evidence
The only published pharmacological study of 2-FA appeared in 2025.[3] In mice, 2-FA produced dose-dependent locomotor stimulation comparable in magnitude to methamphetamine. In rats trained to distinguish methamphetamine from saline, 2-FA fully substituted for the methamphetamine cue — indicating that the two compounds produce similar internal states.
The authors concluded that 2-FA carries abuse potential comparable to methamphetamine, while noting that self-administration studies (the standard measure of how reinforcing a drug is) have not been conducted.[3]
Pharmacokinetics
No human pharmacokinetic study has been published for 2-FA. Oral onset is reported at 15–30 minutes based on community data. Total subjective duration of 2–4 hours is notably shorter than both amphetamine (4–6 hours) and the para-isomer 4-FA, which has a measured half-life of roughly 8–9 hours in humans.[13] Whether 2-FA's brevity reflects faster liver metabolism, rapid redistribution from the brain, or within-session tolerance is unknown.
Metabolic pathways have not been directly studied. Data from the N-methyl homolog 2-FMA suggest that N-demethylation (which yields 2-FA as a metabolite), hydroxylation, and conjugation are likely routes.[1] inferred
Forensic blood concentrations provide limited reference points: 0.028–0.37 mg/kg in Danish DUID cases[2] and approximately 89 µg/L in a fatal polydrug case in Germany.[4] These cannot be interpreted as dose-response data without controlled dosing studies.
Neuroscience[edit]
Neuroscience
No neuroimaging or neurochemical study has been published for 2-FA. The framework below is derived from established amphetamine neuroscience, applied to 2-FA on the basis of its demonstrated methamphetamine-like behavioural profile.[3]
Where it acts
Amphetamine-type releasing agents elevate dopamine in the nucleus accumbens (the brain's core reward hub) and norepinephrine across cortical arousal circuits. At moderate doses, this boosts prefrontal cortex function — sharpening focus, organising thought, and sustaining motivation. At higher doses, the same circuits overshoot: excessive catecholamine signalling flips from cognitive enhancement into anxiety, restlessness, and thought acceleration. 2-FA's full substitution for methamphetamine in animal models[3] implies reward-circuit activation of comparable magnitude.
Why it matters
The Robinson and Berridge model of addiction distinguishes dopaminergic "wanting" (incentive motivation) from "liking" (hedonic pleasure). Amphetamine-class compounds preferentially amplify wanting — the drive to pursue a goal — rather than the pleasure of achieving it. 2-FA's reported profile fits this pattern: users describe motivation and a compulsive compulsive redosing urge, with euphoria that does not scale proportionally with dose. Repeated intermittent exposure to amphetamine-class compounds also produces sensitisation — progressive strengthening of reward-circuit responses — which is thought to underlie escalating patterns of use.
- Why is the duration so short? At 2–4 hours, 2-FA lasts roughly half as long as amphetamine despite increased lipophilicity from fluorination. Faster liver clearance, rapid redistribution from the brain, or acute within-session tolerance could explain it — but no pharmacokinetic data exist to test these hypotheses.
- Does 2-FA cause neurotoxicity? Some para-substituted amphetamines are established neurotoxins. Whether ortho-fluorination produces nerve terminal damage with repeated use is entirely unknown.[8]
Subjective Effects[edit]
Subjective Effects
2-FA produces a state dominated by cognitive and physical stimulation with minimal euphoria or emotional warmth. At common doses the experience reads as clean and functional — wakefulness, sharpened focus, and sustained motivation without the jaw tension, body load, or prosocial push characteristic of more serotonergic stimulants. At higher doses, the balance tips toward anxiety, overstimulation, and diminishing returns rather than proportionally greater reward. Set, setting, and individual neurochemistry modulate the experience substantially; the same dose can feel like productive clarity or jittery restlessness depending on context.
Among the fluoroamphetamine isomers, 2-FA sits closest to d-amphetamine in qualitative character — a primarily dopaminergic stimulant without the MDMA-like prosocial dimension that defines 4-FA. Compared to its N-methyl homolog 2-FMA, 2-FA is reported as less potent and shorter-acting, occupying a niche as a mild, brief-duration functional stimulant rather than a recreational euphoriant.
Effect Grid
At 30–50 mg oral, 2-FA produces its characteristic stimulant profile. Focus enhancement, motivation enhancement, and thought acceleration are clearly present. Wakefulness is pronounced. Cognitive euphoria is possible but described as modest — a mild sense of clarity and drive rather than overt pleasure. The experience is consistently described as functional rather than recreational.
Appetite suppression is moderate. Heart rate elevation becomes noticeable. Mild excessive sweating, dehydration sensation, and pupil dilation are common. Bruxism and muscle tension may appear but are less prominent than with more serotonergic stimulants like 4-FA.
This is the dose range most commonly reported for productive use. Total duration is 2–4 hours, with the short duration creating potential temptation to redose. Insomnia is possible if taken in the afternoon or evening.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing acceleration · Touch enhancement
Appetite suppression · Dry mouth · Insomnia · Dehydration sensation · Muscle tension · Heart rate perception changes · Physical fatigue · Restlessness · Headache · Excessive sweating · Body high · Constipation · Increased urination · Nausea · Bruxism · Sexual arousal enhancement · Bodily lightness · Respiratory stimulation · Trembling · Motor control enhancement · Abnormal heartbeat · Sexual arousal suppression · Involuntary body movements · Dizziness · Nasal congestion · Tingling / electric sensations · Seizure threshold reduction · Tactile hallucination
Dehydration sensation · Muscle tension · Heart rate perception changes · Physical fatigue · Restlessness · Headache · Excessive sweating · Body high · Constipation · Increased urination · Nausea · Bruxism · Sexual arousal enhancement · Bodily lightness · Respiratory stimulation · Trembling · Motor control enhancement · Sexual arousal suppression · Involuntary body movements · Dizziness · Nasal congestion · Tingling / electric sensations · Seizure threshold reduction · Tactile hallucination
Focus enhancement · Motivation enhancement · Motivation suppression · Analysis enhancement · Information processing enhancement · Thought organization · Creativity enhancement · Aesthetic enhancement · Cognitive dysphoria · Cognitive flexibility · Immersion enhancement · Language enhancement · Memory enhancement · Thought loops
Information processing enhancement · Thought organization · Creativity enhancement · Aesthetic enhancement · Cognitive dysphoria · Cognitive flexibility · Immersion enhancement · Language enhancement · Memory enhancement · Thought loops
Anhedonia · Dysphoria · Emotional suppression · Emotional enhancement · Emotional lability · Mania
Emotional enhancement · Emotional lability
Ego inflation · Social connection · Flow state · Self-control enhancement · Automaticity · Depersonalization
Automaticity · Depersonalization
Timeline
Initial awareness of stimulation beginning — subtle increase in alertness and wakefulness without clear cognitive effects. May be difficult to distinguish from placebo at lower doses.
Stimulation builds steadily. Focus sharpens, wakefulness consolidates, and mild heart rate elevation becomes noticeable. Appetite suppression begins.
Full stimulant effect — clear focus enhancement, motivation, and thought acceleration. Wakefulness is pronounced. Modest cognitive euphoria possible.
Gradual decline in stimulation and focus. Residual wakefulness persists as cognitive effects fade. Onset of fatigue and mild irritability.
Post-stimulant recovery phase — mild fatigue, possible low mood or irritability, residual appetite suppression fading. Not a positive afterglow but rather a catecholamine-depletion recovery period.
⚠ Do not drive or operate heavy machinery during this period, as impaired attention and fatigue may persist for several hours after subjective effects resolve.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 5.5 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · methamphetamine · methylphenidate
Toxicity
No lethal dose has been established for 2-FA in any species, and no controlled toxicity study has been published. The toxic dose threshold in humans is unknown.
Acute toxicity
The primary acute danger is sympathomimetic overstimulation: rapid heart rate, elevated blood pressure, overheating, and potentially dangerous heart rhythms.[13] At high doses, amphetamine-type stimulants can trigger paranoia, hallucinations, and delusional thinking, as well as seizures, muscle breakdown, and cardiovascular collapse.
Published case data are sparse. Three Danish driving cases (2010) involved 2-FA alongside amphetamine with no severe acute toxicity.[2] A fatal German case (2019) was attributed to respiratory depression from designer benzodiazepines, not to 2-FA alone.[4]
Liver toxicity
No liver toxicity data exist for 2-FA. The para-isomer 4-FA increases liver cell damage in laboratory assays;[12] whether ortho-halogenation poses a comparable risk is unknown — a significant gap for anyone using the compound repeatedly.
Heart and circulation
All standard amphetamine cardiovascular dangers — high blood pressure, rapid heart rate, coronary vessel spasm — apply fully to 2-FA. The para-isomer 4-FA has been linked to bleeding strokes and a specific form of heart failure; 2-FA's presumed lower serotonin activity may reduce these specific risks, but this is inferred, not measured. inferred
Psychological Risks
No controlled study has assessed psychological risks specific to 2-FA. Class-level risks for amphetamine-type stimulants include:
- Stimulant psychosis: High doses, prolonged wakefulness, or repeated dosing can produce paranoia, delusions, and hallucinations. Sleep deprivation amplifies the risk.
- Anxiety and panic: Doses above the common range shift the experience toward anxiety and overstimulation rather than greater euphoria.
- Mood disturbance: dopamine depletion after use can cause low mood, irritability, and anhedonia during recovery.
- Compulsive redosing: The short duration (2–4 hours) combined with methamphetamine-like internal cues[3] creates conditions that encourage repeated dosing, escalating all risks.
Tolerance & Dependence
No published study has examined tolerance or dependence specific to 2-FA.
Tolerance builds with repeated use, driven by dopamine downregulation and depletion of presynaptic dopamine stores. Community estimates suggest a tolerance half-life of roughly five days. safety citation needed
Cross-tolerance with other dopaminergic stimulants — amphetamine, methamphetamine, methylphenidate, cocaine — is expected.
Dependence is rated moderate. Rodent data showing full methamphetamine substitution[3] indicate significant abuse potential.
Withdrawal has not been characterised for 2-FA specifically. Amphetamine withdrawal produces fatigue, excessive sleep, appetite enhancement, low mood, and slowed movement — uncomfortable but not medically dangerous.
Contraindications
9 knownAbsolute:
- Concurrent MAOI use: Risk of hypertensive crisis and dangerous serotonin overload in the brain. Applies to all monoamine releasing agents without exception.
- Severe heart conditions: Uncontrolled high blood pressure, recent heart attack, structural heart disease, or significant rhythm abnormalities. The catecholamine surge from 2-FA imposes dangerous cardiovascular stress.
Relative:
- Seizure disorders: Stimulants may lower the seizure threshold; compounded by sleep deprivation.
- Anxiety disorders: norepinephrine activation may trigger panic attacks or worsen generalised anxiety.
- Psychotic spectrum conditions: Dopamine stimulation can precipitate or worsen psychosis in predisposed individuals.
- Overactive thyroid: Additive sympathomimetic effects.
- Pregnancy: Amphetamine-class compounds may restrict blood flow to the placenta. safety citation needed
- Liver impairment: Reduced clearance could prolong exposure and increase toxicity.
Drug Interactions
Serotonergic combinations — serotonin syndrome risk: These combinations can cause muscle rigidity, dangerous overheating, and altered consciousness — a potentially fatal response.[14]
- MAOIs: Combining 2-FA with an MAOI risks hypertensive crisis and serotonin syndrome. This applies to irreversible MAOIs (phenelzine, tranylcypromine), reversible MAOIs (moclobemide), and dietary MAOIs (harmaline, harmine in ayahuasca). safety citation needed
- Tramadol: Rated lethal in community interaction databases. Tramadol combines opioid, serotonin-reuptake, and weak monoamine oxidase-inhibiting activity; combined with 2-FA, monoamine levels reach dangerous heights. Tramadol also lowers the seizure threshold independently. safety citation needed
Sympathomimetic combinations — cardiovascular risk: Combining 2-FA with other stimulants adds cardiovascular stress — compounded heart rate, blood pressure, and rhythm disturbances.
- PCP: Rated dangerous in community interaction databases. PCP's cardiovascular stimulation and elevated psychosis risk, layered on 2-FA's catecholamine activation, create additive danger. safety citation needed
CNS depressant combinations: alcohol, GHB/GBL, benzodiazepines, and opioids combined with stimulants mask intoxication from both drug classes. The fatal 2-FA polydrug case[4] illustrates this: designer benzodiazepines combined with a stimulant led to positional asphyxia.
Harm Reduction[edit]
Forms & Identification
2-FA is a white powder visually indistinguishable from dozens of other stimulants. Standard GC-MS cannot tell it apart from its positional isomers 3-FA and 4-FA[2] — meaning a batch labelled "2-FA" could contain 4-FA, which carries greater serotonergic toxicity risk.[12]
Reagent testing narrows the field but cannot confirm positional isomer identity. Laboratory analysis through services such as Energy Control or DrugsData is the only reliable option for higher confidence.
Guidelines
- Weigh every dose on a milligram-scale (0.001 g resolution). Eyeballing powder at the 15–60 mg active range risks significant over- or under-dosing.
- Start at the low end of the common range with a new batch — potency and purity vary between vendors and lots.
- Oral administration is strongly preferred. Intranasal and vaporised routes produce disproportionate discomfort, faster onset, and greater cardiovascular spike.
- Set a firm redosing limit before the session begins. The short duration (2–4 hours) creates a strong pull to redose; cumulative doses compound cardiovascular risk and extend recovery.
- Avoid dosing within 6–8 hours of planned sleep. Stimulant disruption of sleep architecture outlasts subjective effects.
- Stay hydrated — moderate, regular sips of water rather than forcing large volumes.
Set & Setting
2-FA's functional character makes it tempting to use during work or in social contexts where impairment would go unnoticed. This perceived safety is itself a risk factor — the compound's subtlety can mask accumulating cardiovascular stress during long task sessions.
A calm, low-pressure environment with access to water and the ability to rest reduces the chance of anxiety spiralling at higher doses. Eating a meal beforehand buffers cardiovascular and gastrointestinal effects.
Aftercare & integration. The comedown is typically mild, but cumulative sessions or high doses can produce noticeable dopamine depletion — low mood, irritability, fatigue, and difficulty concentrating for one to two days.
- Sleep: Prioritise a full night of sleep after use. Melatonin at a low dose (0.5–1 mg) may assist if residual wakefulness lingers.
- Nutrition: Stimulants suppress appetite during the session. Eat a balanced meal as effects fade — protein, complex carbohydrates, and electrolytes support recovery.
- Rest days: Allow at least several days between sessions. Frequent use accelerates tolerance and increases dependence risk.
- Self-monitoring: If use begins to feel automatic rather than deliberate — especially redosing before the previous dose has worn off — treat that as an early warning sign.
Recovery & Support
Amphetamine-class dependence is psychologically driven: the compound becomes embedded in routines, productivity expectations, or mood regulation. Physical withdrawal is uncomfortable but not medically dangerous.
If reducing or stopping feels difficult, evidence-based options include cognitive-behavioural therapy (CBT), contingency management, and peer support such as SMART Recovery. No pharmacotherapy is approved specifically for amphetamine-type dependence, but a clinician can address co-occurring conditions — depression, ADHD, anxiety — that often drive stimulant use.
Anonymous, judgement-free support is available through harm reduction organisations and online peer communities.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency:
Most experiences involve manageable discomfort at worst. Seek immediate help if any of the following occur: chest pain or pressure, seizure, loss of consciousness, body temperature hot enough to feel through clothing, confusion that does not resolve, or signs of psychosis (paranoia, hallucinations, aggressive agitation).
Immediate steps:
- 1. Call emergency services.
- 2. Move the person to a cool, quiet space. Remove excess clothing if overheating.
- 3. If unconscious but breathing, place in the recovery position (on their side, airway clear).
- 4. Do not restrain unless there is immediate danger of self-harm.
- 5. Do not induce vomiting.
- 6. Monitor breathing and consciousness until help arrives.
What to tell the dispatcher:
Name the substance (2-FA / 2-fluoroamphetamine), estimated dose, time taken, and current symptoms. Mention any other substances taken. Good Samaritan laws in many jurisdictions protect callers from prosecution for drug-related emergencies — calling for help is always the right decision.
Legal Status[edit]
Legal Status
2-FA occupies a legal grey area in most jurisdictions, covered by structural analog provisions or blanket NPS legislation rather than explicit scheduling.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled; Federal Analogue Act applies | Under 21 U.S.C. § 813, 2-FA may be treated as Schedule I when intended for human consumption, as a structural analog of Schedule II amphetamine. Not tested in case law for 2-FA specifically.citation needed |
| United Kingdom | Controlled under Psychoactive Substances Act 2016[6] | Production, supply, possession with intent to supply, import, and export criminalised. Maximum 7 years imprisonment.safety citation needed |
| Germany | Controlled under NpSG (Neue-psychoaktive-Stoffe-Gesetz)[5] | In force November 26, 2016. Production, import with intent to market, administration to others, and trading are punishable. Possession is not independently penalised under NpSG. |
| Canada | Likely Schedule I (CDSA) as amphetamine analog | No specific scheduling order identified. Structural analogy to amphetamine likely places it under Schedule I of the Controlled Drugs and Substances Act.citation needed |
| Australia | Likely Schedule 9 (prohibited substance) | Controlled as an analog of amphetamine under state and federal scheduling. 2-FA does not appear to be specifically named in the Poisons Standard.citation needed |
| Sweden | Flagged via EMCDDA Early Warning System (2012)[5] | National scheduling status not confirmed from primary sources. |
| Netherlands | Status uncertain | The para-isomer 4-FA was placed in Schedule I of the Opium Act in May 2017. 2-FA scheduling has not been specifically confirmed. |
Legal status changes frequently and varies by jurisdiction. This article does not constitute legal advice. Individuals should verify their local law before possessing, importing, or distributing any controlled or potentially controlled substance.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 5.5 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · methamphetamine · methylphenidate
Toxicity
No lethal dose has been established for 2-FA in any species, and no controlled toxicity study — acute, subacute, or chronic — has been published. The toxic dose threshold in humans is unknown.
Acute toxicity
The primary acute danger is sympathomimetic overstimulation: rapid heart rate, elevated blood pressure, vasoconstriction, overheating, and potentially dangerous heart rhythms.[14] At high doses, amphetamine-type stimulants can trigger stimulant psychosis, seizures, muscle breakdown, and cardiovascular collapse. Whether 2-FA carries organ-specific toxicity beyond standard amphetamine-class risks is unknown.
Published case data are sparse. Three Danish driving-under-the-influence cases (2010) involved 2-FA alongside amphetamine with no severe acute toxicity.[2] A fatal German case (2019) involved positional asphyxia during polydrug intoxication; death was attributed to respiratory depression from designer benzodiazepines, not to 2-FA alone.[4]
Liver toxicity
No liver toxicity data exist for 2-FA. Research on the para-isomer 4-FA showed that para-halogenation of amphetamine increases liver cell damage in laboratory assays.[8] Whether ortho-halogenation poses a comparable risk is unknown — a significant gap for anyone using the compound repeatedly.
Heart and circulation
The para-isomer 4-FA has been linked to bleeding strokes and a specific form of heart failure (takotsubo cardiomyopathy), attributed partly to its serotonin activity. 2-FA's presumed lower serotonin activity may reduce these specific risks, but all standard amphetamine cardiovascular dangers — high blood pressure, rapid heart rate, coronary vessel spasm — apply fully. inferred
Psychological Risks
No controlled study has assessed psychological risks specific to 2-FA. Class-level risks for amphetamine-type stimulants include:
- Stimulant psychosis: paranoia, delusions, and hallucinations, emerging with high doses, prolonged wakefulness, or repeated dosing. Sleep deprivation amplifies the risk.
- Anxiety and panic: Doses above the common range shift the experience toward anxiety and overstimulation rather than greater euphoria.
- Mood disturbance: dopamine depletion after stimulant use can produce low mood, irritability, and anhedonia during recovery.
- Compulsive redosing: The short duration (2–4 hours) combined with methamphetamine-like internal cues[3] creates conditions that encourage repeated dosing, with cumulative dose escalation increasing all risks.
Tolerance & Dependence
No published study has examined tolerance or dependence specific to 2-FA.
Tolerance to stimulant and euphoric effects develops with repeated use, driven by dopamine downregulation and depletion of presynaptic dopamine stores. Community estimates suggest a tolerance half-life of roughly five days. safety citation needed
Cross-tolerance with other dopaminergic stimulants (amphetamine, methamphetamine, methylphenidate, cocaine) is expected.
Dependence is rated moderate by community consensus. Rodent data showing full substitution for methamphetamine[3] indicate an internal drug experience consistent with significant abuse potential.
Withdrawal has not been characterised for 2-FA specifically. Amphetamine withdrawal typically produces fatigue, excessive sleep, appetite enhancement, low mood, and slowed movement. It is not medically dangerous but can be functionally debilitating.
Contraindications
9 knownAbsolute:
- Concurrent MAOI use: Risk of hypertensive crisis and serotonin syndrome. Applies to all monoamine releasing agents without exception.
- Severe heart conditions: Uncontrolled high blood pressure, recent heart attack, structural heart disease, or significant rhythm abnormalities. The catecholamine surge from 2-FA imposes dangerous cardiovascular stress.
Relative:
- Seizure disorders: Stimulants may lower the seizure threshold; compounded by sleep deprivation.
- Anxiety disorders: norepinephrine activation may trigger panic attacks or worsen generalised anxiety.
- Psychotic spectrum conditions: Dopamine stimulation can precipitate or worsen psychosis in predisposed individuals.
- Overactive thyroid: Additive sympathomimetic effects.
- Pregnancy: Amphetamine-class compounds pose risk of restricted blood flow to the placenta. safety citation needed
- Liver impairment: If 2-FA is cleared by the liver as predicted, reduced clearance could prolong exposure and increase toxicity.
Drug Interactions
Serotonergic combinations — serotonin syndrome risk: Combining 2-FA with serotonergic agents risks serotonin syndrome, a potentially fatal condition involving muscle rigidity, dangerous overheating, and altered consciousness.[15]
- MAOIs: The combination of any monoamine releasing agent with an MAOI is contraindicated — risk of hypertensive crisis and serotonin syndrome. This applies to irreversible MAOIs (phenelzine, tranylcypromine), reversible MAOIs (moclobemide), and dietary MAOIs (harmaline, harmine in ayahuasca). safety citation needed
- Tramadol: Rated lethal in community interaction databases. Tramadol combines opioid, serotonin-reuptake, and weak monoamine oxidase-inhibiting activity; combined with a norepinephrine-releasing agent, synaptic monoamine concentrations reach dangerous levels. Tramadol also lowers the seizure threshold independently. safety citation needed
Sympathomimetic combinations — cardiovascular risk: Combining 2-FA with other stimulants (cocaine, other amphetamines, high-dose caffeine) produces additive cardiovascular stress — compounded rapid heart rate, elevated blood pressure, and rhythm disturbances.
- PCP: Rated dangerous in community interaction databases. PCP's combination of NMDA antagonism and cardiovascular stimulation, layered on 2-FA's catecholamine activation, creates additive cardiovascular stress and markedly elevated psychosis risk. safety citation needed
CNS depressant combinations: alcohol, GHB/GBL, benzodiazepines, and opioids combined with stimulants mask intoxication signs from both drug classes. The fatal polydrug case involving 2-FA[4] illustrates this pattern: designer benzodiazepines combined with stimulants resulted in positional asphyxia.
Harm Reduction[edit]
Forms & Identification
2-FA is visually indistinguishable from dozens of other white-powder stimulants, and standard GC-MS cannot tell it apart from its positional isomers 3-FA and 4-FA.[2] Reagent testing narrows the field but cannot confirm positional isomer identity. The practical implication: a bag labelled "2-FA" could contain a different fluoroamphetamine isomer with a substantially different risk profile — 4-FA, for example, carries greater serotonergic toxicity risk.[8]
For higher confidence, laboratory analysis through services such as Energy Control or DrugsData is the only reliable option. At minimum, reagent testing rules out entirely different substance classes.
Guidelines
- Weigh every dose on a milligram-scale (0.001 g resolution). Eyeballing powder at the 15–60 mg active range risks significant over- or under-dosing.
- Start at the low end of the common range if using a new batch — potency and purity vary between vendors and lots.
- Oral administration is strongly preferred. Intranasal and vaporised routes produce disproportionate discomfort and faster onset, increasing cardiovascular spike and redosing temptation.
- Set a firm redosing limit before the session begins. The short duration (2–4 hours) creates a strong pull to redose; cumulative doses compound cardiovascular risk and extend the recovery period.
- Avoid dosing within 6–8 hours of planned sleep. Even a short-acting stimulant can disrupt sleep architecture for longer than subjective effects last.
- Stay hydrated but do not overhydrate — moderate, regular sips of water rather than forcing large volumes.
Set & Setting
2-FA's functional character makes it tempting to use in work or social contexts where impairment would be noticed. This perceived safety is itself a risk factor — the compound's subtlety can mask accumulating cardiovascular stress, especially during long task sessions.
A calm, low-pressure environment with access to water and the ability to rest reduces the chance of anxiety spiralling at higher doses. Eating a meal beforehand buffers the cardiovascular and gastrointestinal effects of stimulant use.
Aftercare & integration. The comedown from 2-FA is typically mild compared to longer-acting stimulants, but cumulative sessions or high doses can produce noticeable dopamine depletion — low mood, irritability, fatigue, and difficulty concentrating for one to two days.
- Sleep: Prioritise a full night of sleep after use. Melatonin at a low dose (0.5–1 mg) may assist if residual wakefulness lingers.
- Nutrition: Stimulants suppress appetite during the session. Eat a balanced meal as effects fade — protein, complex carbohydrates, and electrolytes support neurochemical recovery.
- Rest days: Allow at least several days between sessions. Frequent use accelerates tolerance, extends recovery, and increases dependence risk.
- Self-monitoring: If use begins to feel automatic rather than deliberate — especially redosing before the previous dose has fully worn off — treat that pattern as an early warning sign.
Recovery & Support
Amphetamine-class dependence is psychologically driven: the compound becomes embedded in routines, productivity expectations, or mood regulation. Physical withdrawal is uncomfortable but not medically dangerous.
If reducing or stopping use feels difficult, evidence-based options include cognitive-behavioural therapy (CBT), contingency management, and peer support groups such as SMART Recovery. No pharmacotherapy is approved specifically for amphetamine-type dependence, but a clinician can address co-occurring conditions (depression, ADHD, anxiety) that often drive stimulant use.
Anonymous, judgement-free support is available through harm reduction organisations and online peer communities. Seeking help is a practical decision, not a moral one.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency:
Most 2-FA experiences involve manageable discomfort at worst. Seek immediate help if any of the following occur: chest pain or pressure, seizure activity, loss of consciousness, body temperature hot enough to feel through clothing, confusion or disorientation that does not resolve, or signs of psychosis (paranoia, hallucinations, aggressive agitation).
Immediate steps:
- 1. Call emergency services.
- 2. Move the person to a cool, quiet space. Remove excess clothing if overheating.
- 3. If unconscious but breathing, place in the recovery position (on their side, airway clear).
- 4. Do not restrain unless there is immediate danger of self-harm.
- 5. Do not induce vomiting.
- 6. Monitor breathing and consciousness until help arrives.
What to tell the dispatcher:
Name the substance (2-FA / 2-fluoroamphetamine), estimated dose, time taken, and current symptoms. Mention any other substances taken. Good Samaritan laws in many jurisdictions protect callers from prosecution for drug-related emergencies — calling for help is always the right decision.
Legal Status[edit]
Legal Status
2-FA occupies a legal grey area in most jurisdictions, typically covered by structural analog provisions or blanket NPS legislation rather than explicit scheduling. No jurisdiction has individually scheduled 2-FA by name in primary controlled substances legislation as of May 2026.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled; Federal Analogue Act applies | Under 21 U.S.C. § 813, 2-FA may be treated as Schedule I when intended for human consumption, as a structural analog of Schedule II amphetamine. Not tested in case law for 2-FA specifically.citation needed |
| United Kingdom | Controlled under Psychoactive Substances Act 2016[6] | Production, supply, possession with intent to supply, import, and export criminalised. Maximum 7 years imprisonment.safety citation needed |
| Germany | Controlled under NpSG (Neue-psychoaktive-Stoffe-Gesetz)[5] | In force November 26, 2016. Production, import with intent to market, administration to others, and trading are punishable. Possession is not independently penalised under NpSG. |
| Canada | Likely Schedule I (CDSA) as amphetamine analog | No specific scheduling order identified. Structural analogy to amphetamine likely places it under Schedule I of the Controlled Drugs and Substances Act.citation needed |
| Australia | Likely Schedule 9 (prohibited substance) | Controlled as an analog of amphetamine under state and federal scheduling. 2-FA does not appear to be specifically named in the Poisons Standard.citation needed |
| Sweden | Flagged via EMCDDA Early Warning System (2012)[5] | National scheduling status not confirmed from primary sources. |
| Netherlands | Status uncertain | The para-isomer 4-FA was placed in Schedule I of the Opium Act in May 2017. 2-FA scheduling has not been specifically confirmed. |
The legal landscape relies on analog and blanket NPS provisions rather than explicit scheduling, creating enforcement ambiguity and jurisdictional inconsistency. Individuals should assume 2-FA is likely controlled in any jurisdiction where amphetamine is a scheduled substance, as analog provisions typically capture structurally similar compounds intended for psychoactive use.
Frequently asked questions
How long does 2-FA last?
Total duration by route of administration — Oral: 2 – 4 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for 2-FA?
Psychedex publishes a dosage table for 2-FA on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with 2-FA?
The highest-severity documented interactions for 2-FA: MAOIs (Lethal), 5-HTP, Tryptophan (Dangerous), Alpha-2 adrenergic receptor antagonist (Dangerous), Anticholinergics (Dangerous), Antipsychotics (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is 2-FA addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for 2-FA: tolerance builds moderate; full reset takes 5.5 days; cross-tolerance develops with amphetamine, methamphetamine, methylphenidate, cocaine, dopaminergic stimulants. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abcdIshii A, Sato K, Kusakabe K, Kato N, Wada T (2023) Identification and Quantitative Analysis of 2-Fluoromethamphetamine and Its Metabolites in Human Urine — Journal of Analytical Toxicology doi:10.1093/jat/bkac026
- [2]
- [3]
- [4] ^abcdLehmann S, Sczyslo A, Froch-Cortis J, Rothschild MA, Thevis M, Andresen-Streichert H, Mercer-Chalmers-Bender K (2019) Organ distribution of diclazepam, pyrazolam and 3-fluorophenmetrazine — Forensic Science International doi:10.1016/j.forsciint.2019.109959
- [5]
- [6]
references
- [1] ^abcdIshii A, Sato K, Kusakabe K, Kato N, Wada T (2023) Identification and Quantitative Analysis of 2-Fluoromethamphetamine and Its Metabolites in Human Urine — Journal of Analytical Toxicology doi:10.1093/jat/bkac026
- [2]
- [3]
- [4] ^abcdLehmann S, Sczyslo A, Froch-Cortis J, Rothschild MA, Thevis M, Andresen-Streichert H, Mercer-Chalmers-Bender K (2019) Organ distribution of diclazepam, pyrazolam and 3-fluorophenmetrazine — Forensic Science International doi:10.1016/j.forsciint.2019.109959
- [5]
- [6]